Pulmonx Corporation (LUNG) reported Q2 EPS of ($0.40), $0.01 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.77 million.
GUIDANCE:
Pulmonx Corporation sees FY2022 revenue of $55-60 million, versus the consensus of $58.5 million.